Quantcast

Exosome Diagnostics Appoints Johan Skog, Ph.D., As Director of Genetics Research

September 12, 2008

NEW YORK, Sept. 12 /PRNewswire/ — Exosome Diagnostics, Inc. today announced the appointment of Johan Skog, Ph.D., as director of genetics research. In this role, Dr. Skog will oversee the research program that underlies the company’s development of its blood-based diagnostics that can identify cancer-specific genetic mutations.

Dr. Skog is the primary discoverer and inventor of Exosome Diagnostics’ core technology that has been licensed exclusively to the company by Massachusetts General Hospital. He is also a post-doctoral researcher at the molecular neurogenetics unit of Massachusetts General Hospital. Dr. Skog received his Ph.D. specializing in gene therapy from Umea University in Sweden.

“Dr. Skog’s discoveries are the foundation of our development program to capture diagnostic quantities of genetic mutations in blood,” said James McCullough, chairman & chief executive officer. “His expertise as the inventor of the technology of isolating genetic mutations from circulating exosomes for use as diagnostic and prognostic tools will enable the company to rapidly move forward on its first program, a blood-based diagnostic for brain cancer.”

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology. Exosome’s core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers and that they can be reliably harvested and used as a diagnostic tool for cancers and metabolic diseases. Exosome Diagnostics’ lead program is a blood-based diagnostic test for the management of brain cancer patients. For more information, visit http://www.exosomedx.com/.

Exosome Diagnostics, Inc.

CONTACT: Robert Flamm, Ph.D., robert.flamm@russopartnersllc.com, orDavid Schull, david.schull@russopartnersllc.com, both of Russo Partners,+1-212-845-4226

Web site: http://www.exosomedx.com/




comments powered by Disqus